Oneness Biotech
Market Cap
NT$79.5b
Last Updated
2021/01/21 17:23 UTC
Data Sources
Company Financials
Executive Summary
Oneness Biotech Co., Ltd. operates as a biopharmaceutical company in Taiwan. More Details
Rewards
Risk Analysis
Snowflake Analysis
Flawless balance sheet with acceptable track record.
Share Price & News
How has Oneness Biotech's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 4743 is more volatile than 90% of TW stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: 4743's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of TW stocks.
Market Performance
7 Day Return
7.3%
4743
-1.4%
TW Pharmaceuticals
-0.2%
TW Market
1 Year Return
632.4%
4743
29.9%
TW Pharmaceuticals
28.6%
TW Market
Return vs Industry: 4743 exceeded the TW Pharmaceuticals industry which returned 29.9% over the past year.
Return vs Market: 4743 exceeded the TW Market which returned 28.6% over the past year.
Shareholder returns
| 4743 | Industry | Market | |
|---|---|---|---|
| 7 Day | 7.3% | -1.4% | -0.2% |
| 30 Day | -8.4% | -10.5% | 8.8% |
| 90 Day | -37.8% | -20.2% | 20.6% |
| 1 Year | 632.4%632.4% | 32.1%29.9% | 33.1%28.6% |
| 3 Year | 888.4%888.4% | 37.7%30.3% | 55.3%37.8% |
| 5 Year | 537.3%537.3% | 22.1%11.8% | 135.7%94.2% |
Long-Term Price Volatility Vs. Market
How volatile is Oneness Biotech's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 months ago | Simply Wall St
Are Oneness Biotech's (GTSM:4743) Statutory Earnings A Good Reflection Of Its Earnings Potential?7 months ago | Simply Wall St
We're Hopeful That Oneness Biotech (GTSM:4743) Will Use Its Cash Wisely9 months ago | Simply Wall St
Some Oneness Biotech (GTSM:4743) Shareholders Are Down 35%Valuation
Is Oneness Biotech undervalued compared to its fair value and its price relative to the market?
483.31x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate 4743's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate 4743's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: 4743 is poor value based on its PE Ratio (483.3x) compared to the TW Pharmaceuticals industry average (17.6x).
PE vs Market: 4743 is poor value based on its PE Ratio (483.3x) compared to the TW market (18.4x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 4743's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 4743 is overvalued based on its PB Ratio (8.2x) compared to the TW Pharmaceuticals industry average (2x).
Next Steps
Future Growth
How is Oneness Biotech forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
39.1%
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Oneness Biotech has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Next Steps
- Examine Oneness Biotech's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
Past Performance
How has Oneness Biotech performed over the past 5 years?
-17.4%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 4743 has high quality earnings.
Growing Profit Margin: 4743 became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: 4743 has become profitable over the past 5 years, growing earnings by -17.4% per year.
Accelerating Growth: 4743 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 4743 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (23.3%).
Return on Equity
High ROE: 4743's Return on Equity (1.6%) is considered low.
Next Steps
Financial Health
How is Oneness Biotech's financial position?
Financial Position Analysis
Short Term Liabilities: 4743's short term assets (NT$4.0B) exceed its short term liabilities (NT$157.0M).
Long Term Liabilities: 4743's short term assets (NT$4.0B) exceed its long term liabilities (NT$1.4B).
Debt to Equity History and Analysis
Debt Level: 4743 is debt free.
Reducing Debt: 4743 has not had any debt for past 5 years.
Debt Coverage: 4743 has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: 4743 has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Next Steps
Dividend
What is Oneness Biotech current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 4743's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 4743's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 4743's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 4743's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: 4743 is not paying a notable dividend for the TW market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 4743's dividend in 3 years as they are not forecast to pay a notable one for the TW market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
CEO
Oneness Biotech has no CEO, or we have no data on them.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 6.4%.
Top Shareholders
Company Information
Oneness Biotech Co., Ltd.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Oneness Biotech Co., Ltd.
- Ticker: 4743
- Exchange: GTSM
- Founded: 2008
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: NT$79.521b
- Shares outstanding: 372.47m
- Website: https://www.onenessbio.com.tw
Number of Employees
Location
- Oneness Biotech Co., Ltd.
- No.236, Xinyi Road
- 11th Floor
- Taipei
- 106
- Taiwan
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| 4743 | GTSM (Taipei Exchange) | Yes | Common Stock | TW | TWD | Jun 2009 |
| 6ZD | DB (Deutsche Boerse AG) | GD EACH REP 5 ORD TWD10REGS | DE | EUR | Nov 2020 |
Biography
Oneness Biotech Co., Ltd. operates as a biopharmaceutical company in Taiwan. The company develops ON101, which is in Phase III clinical trials for treating chronic diabetic foot ulcers; and OB318, an anti-...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/01/21 17:23 |
| End of Day Share Price | 2021/01/21 00:00 |
| Earnings | 2020/09/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.